Separate PDQ summaries on Lung Cancer Prevention, Small Cell Lung Cancer Treatment, Non-Small Cell Lung Cancer Treatment, and Levels of Evidence for Cancer Screening and Prevention Studies are also available.Evidence of Benefit Associated With ScreeningScreening by low-dose helical computed tomographyBenefitsThere is evidence that screening persons aged 55 to 74 years who have cigarette smoking histories of 30 or more pack-years and who, if they are former smokers, have quit within the last 15 years reduces lung cancer mortality by 20% and all-cause mortality by 6.7%.Magnitude of Effect: 20% relative reduction in lung cancer–specific mortality. Study Design: Evidence obtained from a randomized controlled trial.Internal Validity: Good.Consistency: Not applicable—one randomized trial to date.External Validity: Fair.HarmsBased on solid evidence, screening would lead to false-positive tests in approximately one-quarter of those screened. Most abnormalities would be monitored
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Small Cell Lung Cancer Treatment
Standard Treatment Options for Stages IIA and IIB NSCLCStandard treatment options for stages IIA NSCLC and IIB NSCLC include the following:Surgery.Neoadjuvant chemotherapy.Adjuvant chemotherapy.Radiation therapy.Adjuvant radiation therapy has not been show to improve outcomes in patients with stages II NSCLC.SurgerySurgery is the treatment of choice for patients with stage II NSCLC. A lobectomy, pneumonectomy, or segmental resection, wedge resection, or sleeve resection may be performed as appropriate. Careful preoperative assessment of the patient's overall medical condition, especially the patient's pulmonary reserve, is critical in considering the benefits of surgery. Despite the immediate and age-related postoperative mortality rate, a 5% to 8% mortality rate with pneumonectomy or a 3% to 5% mortality rate with lobectomy can be expected. Evidence (surgery):The Cochrane Collaboration group reviewed 11 randomized trials with a total of
Standard Treatment Options for Stages IA and IB NSCLCStandard treatment options for stage IA NSCLC and IB NSCLC include the following:Surgery.Radiation therapy.Chemotherapy and radiation therapy have not been shown to improve outcomes in stage I NSCLC that has been completely resected.SurgerySurgery is the treatment of choice for patients with stage I NSCLC. A lobectomy or segmental, wedge, or sleeve resection may be performed as appropriate. Patients with impaired pulmonary function are candidates for segmental or wedge resection of the primary tumor. Careful preoperative assessment of the patient's overall medical condition, especially the patient's pulmonary reserve, is critical in considering the benefits of surgery. The immediate postoperative mortality rate is age related, but a 3% to 5% mortality rate with lobectomy can be expected.Evidence (surgery):The Lung Cancer Study Group conducted a randomized study (LCSG-821) that compared lobectomy
Treatment of recurrent small cell lung cancer may include the following: Radiation therapy as palliative therapy to relieve symptoms and improve quality of life. Chemotherapy as palliative therapy to relieve symptoms and improve quality of life. Laser therapy,surgical placement of devices to keep the airways open,and/or internal radiation therapy,as palliative therapy to relieve symptoms and ...
There are different types of treatment for patients with non-small cell lung cancer. Different types of treatments are available for patients with non-small cell lung cancer. Some treatments are standard (the currently used treatment),and some are being tested in clinical trials. Before starting treatment,patients may want to think about taking part in a clinical trial. A treatment clinical ..
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Description of the EvidenceUpdated statistics with estimated new cases and deaths for 2013 (cited American Cancer Society as reference 1).This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.